133 results
6-K
EX-99.4
HCM
HUTCHMED (China) Limited
8 Apr 24
Current report (foreign)
6:03am
Limited and Air China Limited.
Mr To’s career in China spans more than 45 years. He is the original founder of the China healthcare business of Hutchison … , biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
2 Apr 24
Current report (foreign)
6:03am
global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.
Guided by the motto, “Start
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
of the year, and from an anti-corruption crackdown of the healthcare sector in China in the second half of 2023. Hospital access and related activities … and material sustainability topics for HUTCHMED, including (i) climate action; (ii) access to healthcare; (iii) human capital; (iv) ethics and transparency
6-K
EX-99.1
lnc11x7 wcw3ceo4653
30 Jan 24
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
6:17am
6-K
EX-99.1
0lmq1ft
21 Dec 23
Current report (foreign)
6:14am
6-K
EX-99.2
9fp4uvay
13 Dec 23
Current report (foreign)
6:04am
6-K
EX-99.1
jm0yq
7 Dec 23
Current report (foreign)
6:03am
CORRESP
b4rfgs0ge46coxli9
24 Aug 23
Correspondence with SEC
12:00am
6-K
EX-99.1
ync6wsb72rrt8z8m
21 Aug 23
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
6:10am
6-K
EX-99.1
0cbcx5 4o
31 Jul 23
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
7:31am
6-K
EX-99.1
gq5981a7bsy
13 Jul 23
HUTCHMED Announces Changes to Board of Directors and Technical Committee
6:03am
6-K
EX-99.3
4anywm5v
11 Apr 23
2022 Annual Report and Notice of Annual General Meeting
6:04am
6-K
EX-99.1
oo5w3n09js1 jyge
8 Sep 22
Current report (foreign)
6:12am
6-K
EX-99.1
pmpmg93 xc6ne9bitf7y
8 Aug 22
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
6:24am
6-K
EX-99.1
z52tmfjv3htv3chg5
1 Aug 22
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
7:33am
CORRESP
3auzrrwa1 tv
8 Jun 22
Correspondence with SEC
12:00am
6-K
EX-99.1
c6f7bynq heu1co
16 May 22
Appointment of Non–Executive Director
7:24am
6-K
EX-99.3
148hy wzjri6
23 Mar 22
2021 Annual Report and Notice of Annual General Meeting
6:35am